Therapeutic Immune Regulation – TIR

Topics

• Abscopal effects of local tumor treatments like radiation, intra-tumoral injections and mechanical ablation that promote systemic anti-tumor immune responses.
• Development and testing of methods and models of immune responses to cancer and assessing such responses in cancer patients.
• Mechanisms of tumor resistance to immunotherapies and/or tumor escape from immune recognition and killing, including modulation of tumor antigen processing and presentation, alteration of tumor susceptibility to innate and adaptive immune responses, tumor-induced immune suppression, and immune effector cell tolerance/exhaustion.
• Preclinical studies of combinations to improve the efficacy of immunotherapies.

Shared Interests and Overlaps

There are shared interests with Tumor Host Interactions (THI) in the area of the tumor microenvironment. Applications that focus on proposing studies on tumor cell interactions with immune cells and the immune microenvironment that promote tumorigenesis may be reviewed in THI. Applications that focus on antitumor immune regulation, immunotherapy and responses to immunotherapy may be reviewed in TIR.

There are shared interests with Mechanisms of Cancer Therapeutics B (MCTB) in the area of therapeutic resistance. Applications that focus on mechanisms of resistance to cancer therapeutics and strategies to circumvent intrinsic and extrinsic resistance mechanisms may be reviewed in MCTB. Applications that focus on mechanisms of tumor resistance to immunotherapies and/or tumor escape from immune recognition and killing may be reviewed in TIR.

There are shared interests with Radiation Therapeutics and Biology (RTB) in the area of radiolabeled antibodies/antibody constructs, the abscopal immunological effects of radiation therapy, and in vivo imaging to assess response to therapy. Applications with a major focus on radiation physics, radionuclide chemistry, radiation dosimetry, and direct effects of radiation on tumor cells may be reviewed in RTB. Applications more focused on immunological aspects of the therapy may be reviewed in TIR.

There are shared interests in the area of brain tumor therapy with Clinical Neuroimmunology and Brain Tumors (CNBT). Applications that emphasize the immunopathology and immunotherapy of central nervous system tumors (glioma, medulloblastoma, etc.) with focus on therapeutic immune regulation and resistance are reviewed in TIR. Applications that emphasize solely the immunopathology and immunotherapy of central nervous system tumors (glioma, medulloblastoma, etc.) are reviewed in CNBT. 

There are shared interests with Therapeutic Immune Regulation (TIO) in developing non-cellular immunotherapeutics for cancer treatment. Applications that focus on developing therapeutics including antibodies, virus-based agents, vaccines, and immune checkpoint inhibitors and evaluation of their antitumor immune responses may be reviewed in TIO. Applications that focus on understanding the mechanism of tumor resistance to the immunotherapeutics or developing methods and models of immune response to cancer may be reviewed in TIR.

There are shared interests with Cellular Immunotherapy of Cancer (CIC) in areas of therapeutic responses and combination therapies for cancer. Applications that focus on developing CAR-T and other cellular therapies and evaluating their antitumor effects and associated toxicities may be reviewed in CIC. Applications that focus on mechanisms of tumor resistance to cellular therapies such as CAR-T cells may be reviewed in TIR.

There are shared interests with Clinical Oncology (CONC) in the area of cancer clinical trial. Applications that focus on therapeutic clinical trials including combined modality therapy may be reviewed in CONC. Applications that focus on preclinical and early clinical studies of immunotherapy strategies may be reviewed in TIR.